Dr. Shane Johnson, SVP and GM of BayMedica, InMed’s subsidiary, joins Benzinga’s All Access Conference on June 17, 2022.
Dr. Johnson talks about how manufacturing techniques used to produce many pharmaceutical products such as biosynthesis can be used produce bioidentical rare cannabinoids that provide the consistency and purity needed to supply the health and wellness sector. He talks about the recent launch of several rare cannabinoids such as delta-9 THCV and CBDV.
A peer-reviewed scientific study entitled “Rare phytocannabinoids exert anti-inflammatory effects on human keratinocytes via the endocannabinoid system and MAPK signalling pathway” has been published in the International
InMed’s CEO, Mr. Eric A. Adams, presents at the Emerging Growth Conference. This virtual presentation was given on March 8th, 2023. In the presentation, Mr.
InMed’s Senior VP, Preclinical Research and Development, Dr. Eric Hsu, shares results from early neurodegenerative disease studies demonstrating how specific cannabinoids induced neuroprotective effects and
© Copyright 2023 InMed Pharmaceuticals Inc.
"*" indicates required fields